Insilico Medicine is a biotechnology firm that utilizes generative AI to drive the discovery and development of new drugs, with a focus on addressing unmet medical needs.
Insilico Medicine reported a 40% objective response rate at the 130 mg dose of ISM6331 in a small group of participants with mesothelioma.
Insilico Medicine selected ISM1354 as a preclinical small molecule candidate targeting GIPR for potential treatment of obesity and related conditions.
Insilico Medicine released an open toolkit with an AI benchmark, specialized language models and an agent platform for aging research. Its top model recorded the highest overall score among 26 systems tested on LongevityBench.
Insilico Medicine dosed the first patient in a Phase III trial of Rentosertib for idiopathic pulmonary fibrosis. The study will enroll about 320 participants across 47 centers in China.
Six proteomic aging clocks estimated lower biological ages among rentosertib recipients in a Phase IIa trial involving 42 patients with idiopathic pulmonary fibrosis.
Insilico Medicine will join the HKEX Tech 100 Index on September 14 after changes to the index methodology.
Insilico Medicine will present first in human Phase 1 data for ISM6331 at ESMO Congress 2026 in Madrid.
Insilico Medicine and Bora Pharmaceuticals have announced plans for a strategic alliance combining Insilico's AI platform with Bora's manufacturing capabilities in a potential collaboration valued at over 2.5 billion dollars.
Insilico Medicine and China Medical System Holdings have announced an expanded partnership to co-develop AI-powered treatments for central nervous system diseases, with potential milestone payments of up to 1.2 billion RMB.
Insilico Medicine and Takeda have announced a collaboration to use Insilico’s Pharma.AI platform for identifying and developing novel drug candidates. The agreement could reach a total value of about $600 million, including upfront and milestone payments.
Insilico Medicine and SK Biopharmaceuticals have entered a research and development collaboration worth up to $2.5 billion to develop drug candidates for neuroimmune disorders using Insilico’s AI platform.
Insilico Medicine and Human Longevity have announced a collaboration to create a large-scale AI foundation model focused on longevity science, combining advanced multimodal modeling with extensive clinical and genomic datasets.
Suzhou Ribo Life Science and Insilico Medicine have announced a strategic collaboration to accelerate siRNA drug development using AI platforms, combining Ribo's RNAi expertise with Insilico's Pharma.AI technology.
Insilico Medicine has announced ISM0387, the first preclinical drug candidate discovered in the UAE using generative AI, developed in collaboration with the Emirates Drug Establishment and supported by Abu Dhabi institutions.
Insilico Medicine has announced the creation of the industry's first Longevity Board to provide scientific oversight and strategic direction for AI-based aging and drug discovery research. The board will be chaired by Andrew Adams of Eli Lilly and Company.
Harbour BioMed and Insilico Medicine have announced a strategic collaboration to enhance AI-driven antibody discovery and development, combining their technological strengths.
Daily report covering major AI developments and industry news, with both top stories and complete market updates